Survival and Prognostic Factors in Patients With Ovarian Cancer

OBJECTIVE To assess incidence during a 10-year study period and to identify and discuss clinical relevance for prognostic factors of survival within a cohort of Norwegian ovarian cancer patients. METHODS Incidence and prognostic factors of survival within a population-based cohort of ovarian cancer patients from one health region in Norway were examined over the 10-year period 1987 through 1996. A total of 571 histologically verified cases of primary ovarian cancer originally registered either in the Cancer Registry of Norway or in the hospital's discharge registers were included in the study. Pearson χ2 test was used in univariate analyses of cofactors by 5-year survival, and Kaplan-Meier survival curves were computed and tested statistically by the log rank test. A multivariable proportional hazard model (Cox) was applied to assess the prognostic significance of the different covariates. RESULTS The incidence and crude 5-year survival remained stable over the 10-year study period. The standardized incidence rate for the time periods 1987–1991 and 1992–1996 was 11.9/100,000 and 12.5/100,000, respectively. The crude 5-year survival rate for the cohort was 39%, whereas median survival was 32 months. Cox multivariable regression analysis showed that the only independent significant prognostic factors were International Federation of Gynecology and Obstetrics stage (P < .001), size of residual tumor at the end of primary surgery (P < .001), and age at diagnosis (P < .01). Variables such as time period, histologic type and grade, treating hospital, comorbidity, or CA 125 were insignificant in predicting 5-year survival. CONCLUSION The results underline the importance of improved surgical management of ovarian cancer, as residual tumor is the only prognostic factor achievable.

[1]  T. Bjørge,et al.  Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993 , 1998, International journal of cancer.

[2]  V. Torri,et al.  Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). , 1990, British Journal of Cancer.

[3]  K. Bertelsen Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. , 1990, Gynecologic oncology.

[4]  F. Montz,et al.  Inability of polyglycolic acid mesh to inhibit immediate post-radical pelvic surgery adhesions. , 1990, Gynecologic oncology.

[5]  R. Rosenfeld,et al.  Validation of the Charlson Comorbidity Index in Patients With Head and Neck Cancer: A Multi‐institutional Study , 1997, The Laryngoscope.

[6]  L. Mcgowan Epidemiology of ovarian cancer. , 1989, Oncology.

[7]  T. Halvorsen,et al.  Completeness and accuracy of registration of ovarian cancer in the cancer registry of Norway , 2002, International journal of cancer.

[8]  C. Gillis,et al.  Management of ovarian cancer: referral to a multidisciplinary team matters. , 1994, British Journal of Cancer.

[9]  D. Fortune Histological Typing of Ovarian Tumours , 1975 .

[10]  G. Fleuren,et al.  Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors , 1987, Cancer.

[11]  J. Spinelli,et al.  Ovarian Carcinoma: A Multivariate Analysis of Prognostic Factors , 1985, Obstetrics and gynecology.

[12]  H. Stalsberg,et al.  Observer variation in histologic classification of malignant and borderline ovarian tumors. , 1988, Human pathology.

[13]  J. Neijt,et al.  A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. , 1989, European journal of cancer & clinical oncology.

[14]  U. Menon Ovarian cancer screening , 2002, Canadian Medical Association Journal.

[15]  A. Heintz,et al.  Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity , 1986 .

[16]  D.,et al.  Regression Models and Life-Tables , 2022 .

[17]  J. Carstensen,et al.  Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. , 1993, Gynecologic oncology.

[18]  M. Gore,et al.  Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  G. Chêne,et al.  Long-term results and prognostic factors in patients with epithelial ovarian cancer. , 2000, Gynecologic oncology.

[20]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.

[21]  T. Bjørge,et al.  Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954‐1993 , 1997, International journal of cancer.

[22]  B. Lund,et al.  Original article: Prognostic factors for overall survival in patients with advanced ovarian carcinoma , 1991 .

[23]  B. Lund,et al.  Prognostic factors for overall survival in patients with advanced ovarian carcinoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  A. Talerman,et al.  The prognostic variability of ovarian tumor grading by different pathologists. , 1987, Gynecologic oncology.

[25]  D G Altman,et al.  A prognostic model for ovarian cancer , 2001, British Journal of Cancer.

[26]  G. Lyman,et al.  Comorbidity and functional status are independent in older cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Nustad,et al.  The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. , 1999, Obstetrics and gynecology.

[28]  C. Griffiths Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. , 1975, National Cancer Institute monograph.

[29]  J. Berek,et al.  The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. , 1994, American journal of obstetrics and gynecology.

[30]  R. Elashoff,et al.  Primary Cytoreductive Surgery for Epithelial Ovarian Cancer , 1983, Obstetrics and gynecology.

[31]  L. Melton,et al.  Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. , 1984, American journal of obstetrics and gynecology.

[32]  R. Scully Histological Typing of Ovarian Tumours , 1999, World Health Organization. International Histological Classification of Tumours.

[33]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Griffiths Ct Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. , 1975 .

[35]  Steven J Skates,et al.  Screening for ovarian cancer: a pilot randomised controlled trial , 1999, The Lancet.

[36]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[37]  C. la Vecchia,et al.  Epidemiologic pathology of ovarian cancer from the Vaud Cancer Registry, Switzerland. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.